Market Overview

Morgan Stanley Speculates On Potential Abbott Laboratories Transaction

Related ABT
Amid Headline Risk, Barclays Says St. Jude's Pipeline Underestimated
Fed Speakers And Beige Book, Bank Earnings, Rising Crude Take Center Stage
Alere's Shareholders Approve Merger With Abbott (GuruFocus)

In a report published Monday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $45.00 price target on Abbott Laboratories (NYSE: ABT).

In the report, Morgan Stanley noted, “Abbott is a unique healthcare asset, with high exposure to emerging markets and consumer- directed businesses, driving the potential for sustainable double digit earnings growth. Leverage opportunities are highly visible in both Nutritionals and Diagnostics, where peer margins demonstrate the potential for improvement. Expectations are low for the established pharma business, which has come under pressure in the developed markets and presents the potential for reacceleration as emerging market mix grows over time and austerity measures are lapped.”

Abbott Laboratories closed on Friday at $38.56.

Latest Ratings for ABT

Sep 2016JefferiesMaintainsBuy
Aug 2016JefferiesMaintainsBuy
Jul 2016JefferiesMaintainsBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (ABT)

View Comments and Join the Discussion!